Literature DB >> 7772871

Preparation and structural characterization of large heparin-derived oligosaccharides.

A Pervin1, C Gallo, K A Jandik, X J Han, R J Linhardt.   

Abstract

Porcine mucosal heparin was partially depolymerized with heparin lyase I and then fractionated into low-molecular-weight (< 5000) and high-molecular-weight (> 5000) oligosaccharides by pressure filtration. The high-molecular-weight oligosaccharide mixture (approximately 50 wt% of the starting heparin) also contained intact heparin. This intact polymer complicates oligosaccharide purification. Thus, the low-molecular-weight fraction was used to prepare homogeneous oligosaccharides for structural characterization. The low-molecular-weight oligosaccharide mixture was first fractionated by low-pressure gel permeation chromatography into size-uniform mixtures of disaccharides, tetrasaccharides, hexasaccharides, octasaccharides, decasaccharides, dodecasaccharides, tetradecasaccharides and higher oligosaccharides. Each size-fractionated mixture was then purified on the basis of charge by repetitive semi-preparative strong-anion-exchange high-performance liquid chromatography. This approach has led to the isolation of 14 homogeneous oligosaccharides from disaccharide to tetradecasaccharide. The purity of these heparin-derived oligosaccharides was determined by gradient polyacrylamide gel electrophoresis, analytical strong-anion-exchange high-performance liquid chromatography, capillary electrophoresis and one-dimensional nuclear resonance spectroscopy. The structure of these oligosaccharides was established using 600 MHz two-dimensional nuclear resonance spectroscopy. The spectral methods used included homonuclear correlation spectroscopy, nuclear Overhauser effect spectroscopy and heteronuclear multiple quantum coherence spectroscopy. The 1H/1H connectivities of the protons of each sugar residue in an oligosaccharide were established by two-dimensional homonuclear correlation spectroscopy, while 1H/13C assignments were made using 1H inverse detection. One- and two-dimensional nuclear resonance spectroscopic analysis of these heparin oligosaccharides showed two closely related groups of heparin-oligosaccharides are afforded by enzymatic depolymerization of heparin. One group is fully sulphated, having the structures delta UAp2S(1[-->4)-alpha-D-GlcNpS6S(1-->4)-alpha-L-IdoAp2S( 1]n-->4)-alpha- D-GlcNpS6S, where delta UAp is 4-deoxy-alpha-L-threo-hex-4-eno-pyranosyluronic acid, GlcNp is 2-deoxy-2-aminoglucopyranose, IdoAp is idopyranosyluronic acid, S is sulphate and n = 0-6. The other group of oligosaccharides differ in that they contain beta-D-glucuronic acid in place of the alpha-L-iduronic acid residue nearest to the reducing end. The present study describes the isolation and structural elucidation of seven new oligosaccharides: an octasaccharide, two decasaccharides, two dodecasaccharides and two tetradecasaccharides. The utility of two-dimensional nuclear resonance spectroscopy to determine the structure of complex heparin oligosaccharides is also illustrated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772871     DOI: 10.1093/glycob/5.1.83

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  69 in total

1.  Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages.

Authors:  Zhongping Xiao; Wenjing Zhao; Bo Yang; Zhenqing Zhang; Huashi Guan; Robert J Linhardt
Journal:  Glycobiology       Date:  2010-08-20       Impact factor: 4.313

2.  Determination of the primary structure and carboxyl pK (A)s of heparin-derived oligosaccharides by band-selective homonuclear-decoupled two-dimensional (1)H NMR.

Authors:  Khanh Nguyen; Dallas L Rabenstein
Journal:  Anal Bioanal Chem       Date:  2010-10-03       Impact factor: 4.142

3.  Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23.

Authors:  Xijie Yu; Omar A Ibrahimi; Regina Goetz; Fuming Zhang; Siobhan I Davis; Holly J Garringer; Robert J Linhardt; David M Ornitz; Moosa Mohammadi; Kenneth E White
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

Review 4.  CS lyases: structure, activity, and applications in analysis and the treatment of diseases.

Authors:  Robert J Linhardt; Fikri Y Avci; Toshihiko Toida; Yeong Shik Kim; Miroslaw Cygler
Journal:  Adv Pharmacol       Date:  2006

5.  Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation.

Authors:  Jeremy J Wolff; Lianli Chi; Robert J Linhardt; I Jonathan Amster
Journal:  Anal Chem       Date:  2007-01-25       Impact factor: 6.986

6.  Analysis of glycosaminoglycans in stem cell glycomics.

Authors:  Boyangzi Li; Haiying Liu; Zhenqing Zhang; Hope E Stansfield; Jonathan S Dordick; Robert J Linhardt
Journal:  Methods Mol Biol       Date:  2011

7.  Electron detachment dissociation of glycosaminoglycan tetrasaccharides.

Authors:  Jeremy J Wolff; I Jonathan Amster; Lianli Chi; Robert J Linhardt
Journal:  J Am Soc Mass Spectrom       Date:  2006-10-30       Impact factor: 3.109

8.  Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate.

Authors:  Brian K Yeh; Anna V Eliseenkova; Alexander N Plotnikov; David Green; Jared Pinnell; Tulay Polat; Amel Gritli-Linde; Robert J Linhardt; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1.

Authors:  Ronald Copeland; Arun Balasubramaniam; Vaibhav Tiwari; Fuming Zhang; Arlene Bridges; Robert J Linhardt; Deepak Shukla; Jian Liu
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

Review 10.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.